Aikya Investment Management Ltd Increases Stock Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Aikya Investment Management Ltd increased its position in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 416.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,610,503 shares of the company's stock after purchasing an additional 4,523,303 shares during the period. Dr. Reddy's Laboratories makes up 36.9% of Aikya Investment Management Ltd's portfolio, making the stock its 2nd largest holding. Aikya Investment Management Ltd owned about 0.67% of Dr. Reddy's Laboratories worth $88,590,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in RDY. Robeco Institutional Asset Management B.V. lifted its stake in Dr. Reddy's Laboratories by 453.8% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock worth $180,620,000 after purchasing an additional 9,373,412 shares during the last quarter. Fisher Asset Management LLC lifted its stake in shares of Dr. Reddy's Laboratories by 402.5% during the 4th quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company's stock worth $38,981,000 after acquiring an additional 1,977,419 shares during the last quarter. State Street Corp boosted its holdings in Dr. Reddy's Laboratories by 1.9% during the 3rd quarter. State Street Corp now owns 909,905 shares of the company's stock valued at $72,292,000 after acquiring an additional 16,641 shares during the period. Mondrian Investment Partners LTD boosted its holdings in Dr. Reddy's Laboratories by 356.7% during the 4th quarter. Mondrian Investment Partners LTD now owns 648,813 shares of the company's stock valued at $10,245,000 after acquiring an additional 506,752 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its position in Dr. Reddy's Laboratories by 400.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company's stock valued at $8,373,000 after acquiring an additional 427,573 shares during the last quarter. 3.85% of the stock is currently owned by institutional investors.

Remove Ads

Analyst Ratings Changes

RDY has been the subject of a number of recent analyst reports. StockNews.com lowered shares of Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, December 6th. Nomura cut shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research report on Thursday, December 19th.

Dr. Reddy's Laboratories Stock Down 1.8 %

NYSE RDY traded down $0.24 on Tuesday, reaching $13.47. 2,381,066 shares of the stock traded hands, compared to its average volume of 1,270,146. Dr. Reddy's Laboratories Limited has a 12 month low of $12.50 and a 12 month high of $16.89. The company has a market cap of $11.24 billion, a price-to-earnings ratio of 21.45 and a beta of 0.48. The company has a fifty day moving average price of $13.63 and a 200-day moving average price of $14.67. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. As a group, research analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.